Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm
BackgroundEpiscleral brachytherapy is the most common eye-preserving treatment for medium-sized choroidal melanomas. γ-emitting iodine-125 (125I) and β-emitting ruthenium-106 (106Ru) are widely used. The latter is however generally reserved for thinner tumours (
Gespeichert in:
| Veröffentlicht in: | British journal of ophthalmology 2020-01, Vol.104 (1), p.26-32 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 32 |
|---|---|
| container_issue | 1 |
| container_start_page | 26 |
| container_title | British journal of ophthalmology |
| container_volume | 104 |
| creator | Filì, Maria Trocme, Eric Bergman, Louise See, Thonnie Rose Ong André, Helder Bartuma, Katarina Girnita, Leonard All-Eriksson, Charlotta Seregard, Stefan Stålhammar, Gustav |
| description | BackgroundEpiscleral brachytherapy is the most common eye-preserving treatment for medium-sized choroidal melanomas. γ-emitting iodine-125 (125I) and β-emitting ruthenium-106 (106Ru) are widely used. The latter is however generally reserved for thinner tumours ( |
| doi_str_mv | 10.1136/bjophthalmol-2018-313419 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_481022</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2347527455</sourcerecordid><originalsourceid>FETCH-LOGICAL-b425t-f9592dd067b521e871cc8252481e065780be5e06f3a4b75d64cbe56ecfcc4bd83</originalsourceid><addsrcrecordid>eNqNkU1u1TAUhS1ERR-FLSBLTJik-Dr-yxBVFJAqIVXt2LIdR8lrHAc7oXpLYCFsjJXgpzwqxIiRr4---3N0EMJALgFq8d7u49wvvRlDHCtKQFU11AyaZ2gHTKgiyeY52hFCZAUg4By9zHlfvlSAfIHOa9IAURJ2KNyuS--nYQ0VEIG_-5TXjIfYDpOvgHI8j-bb6rFNxvWHgiYzH3DsMJeAXR9THFoz4uBHM8VgMn4clh4bvPSDe5h8zkf214-f_JLjEF6hs86M2b8-vRfo_vrj3dXn6ubrpy9XH24qyyhfqq7hDW1bIqTlFHw51DlFOWUKPBFcKmI9L1VXG2YlbwVzRRDedc4x26r6AlXb3Pzo59XqOQ3BpIOOZtAn6aFUXpeJhNLCv9v4OcXiNi86DNn5sZjycc2aQiNVA4LKgr79B93HNU3FjaY1k5xKxnmh1Ea5FHNOvns6AYg-Rqj_jlAfI9RbhKX1zWnBaoNvnxr_ZFaAegNs2P__2N_T9qwl</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2347527455</pqid></control><display><type>article</type><title>Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm</title><source>PubMed Central</source><creator>Filì, Maria ; Trocme, Eric ; Bergman, Louise ; See, Thonnie Rose Ong ; André, Helder ; Bartuma, Katarina ; Girnita, Leonard ; All-Eriksson, Charlotta ; Seregard, Stefan ; Stålhammar, Gustav</creator><creatorcontrib>Filì, Maria ; Trocme, Eric ; Bergman, Louise ; See, Thonnie Rose Ong ; André, Helder ; Bartuma, Katarina ; Girnita, Leonard ; All-Eriksson, Charlotta ; Seregard, Stefan ; Stålhammar, Gustav</creatorcontrib><description>BackgroundEpiscleral brachytherapy is the most common eye-preserving treatment for medium-sized choroidal melanomas. γ-emitting iodine-125 (125I) and β-emitting ruthenium-106 (106Ru) are widely used. The latter is however generally reserved for thinner tumours (<6 mm). In this study, we compare ocular and patient survival in thicker tumours treated with the respective radioisotope.MethodsAll patients with ≥5.5 mm thick choroidal melanomas who were treated with plaque brachytherapy at a single institution between 1 November 1979 and 31 December 2015 were included (n=571). Size-controlled Cox regression HRs for postbrachytherapy enucleation, repeated brachytherapy and melanoma-related mortality were calculated, as well as Kaplan-Meier disease-specific survival and relative 10-year survival in matched subgroups.Results317 patients were treated with 106Ru and 254 with 125I. The rate of repeated brachytherapy was significantly higher among patients treated with 106Ru (8%) than with 125I (1%, p<0.001). Size-controlled Cox regression HRs for postbrachytherapy enucleation (125I vs 106Ru 0.7, p=0.083) and melanoma-related mortality were not significant (125I vs 106Ru 1.1, p=0.63). Similarly, Kaplan-Meier disease-specific and relative 10-year survival was comparable in matched groups of 5.5–7.4 mm (relative survival 106Ru 59%, 125I 56%) and ≥7.5 mm thick tumours (relative survival 106Ru 46%, 125I 44%).ConclusionsRates of repeated brachytherapy were significantly higher among patients treated with 106Ru versus 125I for thick choroidal melanomas. There were, however, no significant differences in rates of enucleation or patient survival.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjophthalmol-2018-313419</identifier><identifier>PMID: 30910871</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Iodine ; Medical prognosis ; Melanoma ; Metastasis ; Mortality ; Patients ; Radiation therapy ; Radioisotopes ; Skin cancer ; Tumors ; Ultrasonic imaging</subject><ispartof>British journal of ophthalmology, 2020-01, Vol.104 (1), p.26-32</ispartof><rights>Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b425t-f9592dd067b521e871cc8252481e065780be5e06f3a4b75d64cbe56ecfcc4bd83</citedby><cites>FETCH-LOGICAL-b425t-f9592dd067b521e871cc8252481e065780be5e06f3a4b75d64cbe56ecfcc4bd83</cites><orcidid>0000-0001-9401-8911</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30910871$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:142712501$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Filì, Maria</creatorcontrib><creatorcontrib>Trocme, Eric</creatorcontrib><creatorcontrib>Bergman, Louise</creatorcontrib><creatorcontrib>See, Thonnie Rose Ong</creatorcontrib><creatorcontrib>André, Helder</creatorcontrib><creatorcontrib>Bartuma, Katarina</creatorcontrib><creatorcontrib>Girnita, Leonard</creatorcontrib><creatorcontrib>All-Eriksson, Charlotta</creatorcontrib><creatorcontrib>Seregard, Stefan</creatorcontrib><creatorcontrib>Stålhammar, Gustav</creatorcontrib><title>Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>BackgroundEpiscleral brachytherapy is the most common eye-preserving treatment for medium-sized choroidal melanomas. γ-emitting iodine-125 (125I) and β-emitting ruthenium-106 (106Ru) are widely used. The latter is however generally reserved for thinner tumours (<6 mm). In this study, we compare ocular and patient survival in thicker tumours treated with the respective radioisotope.MethodsAll patients with ≥5.5 mm thick choroidal melanomas who were treated with plaque brachytherapy at a single institution between 1 November 1979 and 31 December 2015 were included (n=571). Size-controlled Cox regression HRs for postbrachytherapy enucleation, repeated brachytherapy and melanoma-related mortality were calculated, as well as Kaplan-Meier disease-specific survival and relative 10-year survival in matched subgroups.Results317 patients were treated with 106Ru and 254 with 125I. The rate of repeated brachytherapy was significantly higher among patients treated with 106Ru (8%) than with 125I (1%, p<0.001). Size-controlled Cox regression HRs for postbrachytherapy enucleation (125I vs 106Ru 0.7, p=0.083) and melanoma-related mortality were not significant (125I vs 106Ru 1.1, p=0.63). Similarly, Kaplan-Meier disease-specific and relative 10-year survival was comparable in matched groups of 5.5–7.4 mm (relative survival 106Ru 59%, 125I 56%) and ≥7.5 mm thick tumours (relative survival 106Ru 46%, 125I 44%).ConclusionsRates of repeated brachytherapy were significantly higher among patients treated with 106Ru versus 125I for thick choroidal melanomas. There were, however, no significant differences in rates of enucleation or patient survival.</description><subject>Iodine</subject><subject>Medical prognosis</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Patients</subject><subject>Radiation therapy</subject><subject>Radioisotopes</subject><subject>Skin cancer</subject><subject>Tumors</subject><subject>Ultrasonic imaging</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqNkU1u1TAUhS1ERR-FLSBLTJik-Dr-yxBVFJAqIVXt2LIdR8lrHAc7oXpLYCFsjJXgpzwqxIiRr4---3N0EMJALgFq8d7u49wvvRlDHCtKQFU11AyaZ2gHTKgiyeY52hFCZAUg4By9zHlfvlSAfIHOa9IAURJ2KNyuS--nYQ0VEIG_-5TXjIfYDpOvgHI8j-bb6rFNxvWHgiYzH3DsMJeAXR9THFoz4uBHM8VgMn4clh4bvPSDe5h8zkf214-f_JLjEF6hs86M2b8-vRfo_vrj3dXn6ubrpy9XH24qyyhfqq7hDW1bIqTlFHw51DlFOWUKPBFcKmI9L1VXG2YlbwVzRRDedc4x26r6AlXb3Pzo59XqOQ3BpIOOZtAn6aFUXpeJhNLCv9v4OcXiNi86DNn5sZjycc2aQiNVA4LKgr79B93HNU3FjaY1k5xKxnmh1Ea5FHNOvns6AYg-Rqj_jlAfI9RbhKX1zWnBaoNvnxr_ZFaAegNs2P__2N_T9qwl</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Filì, Maria</creator><creator>Trocme, Eric</creator><creator>Bergman, Louise</creator><creator>See, Thonnie Rose Ong</creator><creator>André, Helder</creator><creator>Bartuma, Katarina</creator><creator>Girnita, Leonard</creator><creator>All-Eriksson, Charlotta</creator><creator>Seregard, Stefan</creator><creator>Stålhammar, Gustav</creator><general>BMJ Publishing Group LTD</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><orcidid>https://orcid.org/0000-0001-9401-8911</orcidid></search><sort><creationdate>20200101</creationdate><title>Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm</title><author>Filì, Maria ; Trocme, Eric ; Bergman, Louise ; See, Thonnie Rose Ong ; André, Helder ; Bartuma, Katarina ; Girnita, Leonard ; All-Eriksson, Charlotta ; Seregard, Stefan ; Stålhammar, Gustav</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b425t-f9592dd067b521e871cc8252481e065780be5e06f3a4b75d64cbe56ecfcc4bd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Iodine</topic><topic>Medical prognosis</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Patients</topic><topic>Radiation therapy</topic><topic>Radioisotopes</topic><topic>Skin cancer</topic><topic>Tumors</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Filì, Maria</creatorcontrib><creatorcontrib>Trocme, Eric</creatorcontrib><creatorcontrib>Bergman, Louise</creatorcontrib><creatorcontrib>See, Thonnie Rose Ong</creatorcontrib><creatorcontrib>André, Helder</creatorcontrib><creatorcontrib>Bartuma, Katarina</creatorcontrib><creatorcontrib>Girnita, Leonard</creatorcontrib><creatorcontrib>All-Eriksson, Charlotta</creatorcontrib><creatorcontrib>Seregard, Stefan</creatorcontrib><creatorcontrib>Stålhammar, Gustav</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Filì, Maria</au><au>Trocme, Eric</au><au>Bergman, Louise</au><au>See, Thonnie Rose Ong</au><au>André, Helder</au><au>Bartuma, Katarina</au><au>Girnita, Leonard</au><au>All-Eriksson, Charlotta</au><au>Seregard, Stefan</au><au>Stålhammar, Gustav</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>104</volume><issue>1</issue><spage>26</spage><epage>32</epage><pages>26-32</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><abstract>BackgroundEpiscleral brachytherapy is the most common eye-preserving treatment for medium-sized choroidal melanomas. γ-emitting iodine-125 (125I) and β-emitting ruthenium-106 (106Ru) are widely used. The latter is however generally reserved for thinner tumours (<6 mm). In this study, we compare ocular and patient survival in thicker tumours treated with the respective radioisotope.MethodsAll patients with ≥5.5 mm thick choroidal melanomas who were treated with plaque brachytherapy at a single institution between 1 November 1979 and 31 December 2015 were included (n=571). Size-controlled Cox regression HRs for postbrachytherapy enucleation, repeated brachytherapy and melanoma-related mortality were calculated, as well as Kaplan-Meier disease-specific survival and relative 10-year survival in matched subgroups.Results317 patients were treated with 106Ru and 254 with 125I. The rate of repeated brachytherapy was significantly higher among patients treated with 106Ru (8%) than with 125I (1%, p<0.001). Size-controlled Cox regression HRs for postbrachytherapy enucleation (125I vs 106Ru 0.7, p=0.083) and melanoma-related mortality were not significant (125I vs 106Ru 1.1, p=0.63). Similarly, Kaplan-Meier disease-specific and relative 10-year survival was comparable in matched groups of 5.5–7.4 mm (relative survival 106Ru 59%, 125I 56%) and ≥7.5 mm thick tumours (relative survival 106Ru 46%, 125I 44%).ConclusionsRates of repeated brachytherapy were significantly higher among patients treated with 106Ru versus 125I for thick choroidal melanomas. There were, however, no significant differences in rates of enucleation or patient survival.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>30910871</pmid><doi>10.1136/bjophthalmol-2018-313419</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-9401-8911</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1161 |
| ispartof | British journal of ophthalmology, 2020-01, Vol.104 (1), p.26-32 |
| issn | 0007-1161 1468-2079 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_481022 |
| source | PubMed Central |
| subjects | Iodine Medical prognosis Melanoma Metastasis Mortality Patients Radiation therapy Radioisotopes Skin cancer Tumors Ultrasonic imaging |
| title | Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T15%3A34%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ruthenium-106%20versus%20iodine-125%20plaque%20brachytherapy%20of%20571%20choroidal%20melanomas%20with%20a%20thickness%20of%20%E2%89%A55.5%20mm&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Fil%C3%AC,%20Maria&rft.date=2020-01-01&rft.volume=104&rft.issue=1&rft.spage=26&rft.epage=32&rft.pages=26-32&rft.issn=0007-1161&rft.eissn=1468-2079&rft_id=info:doi/10.1136/bjophthalmol-2018-313419&rft_dat=%3Cproquest_swepu%3E2347527455%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2347527455&rft_id=info:pmid/30910871&rfr_iscdi=true |